Skip to main content

Table 3 Univariate analysis for survival

From: Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status

  3Y-PFS, % (95% CI) p 3Y-OS % (95% CI) p
Gender   0.301   0.571
  Male 51 (37.7-64.3) 70 (58.3-80.7)
  Female 80 (43.0-117.0) 80 (44.9-115.1)
Smoking   0.793   0.642
  Never 50 (28.2-71.4) 73 (55.4-89.9)
  Ex/current 55 (39.7-71.3) 69 (55.7-82.7)
Alcohol   0.217   0.338
  Never/social 56 (42.0-70.6) 72 (59.7-84.1)
  Heavy 45 (21.0-69.6) 66 (44.1-88.4)
Anatomic site   0.235   0.563
  Tonsil 59 (43.5-73.7) 71 (57.7-84.4)
  Others 44 (21.6-65.8) 69.2 (51.4-87.0)
Clinical stage   0.952   0.930
  III 54 (39.4-68.8) 72 (53.3-92.3)
  IV 53 (38.5-67.5) 61 (42.7-78.7)
T stage   0.005   0.710
  T1-2 63 (47.7-79.1) 77 (64.1-89.5)
  T3-4 37 (17.6-56.8) 61 (42.7-78.7)
N stage   0.750   0.805
  N0-1 54 (39.4-68.8) 73 (53.3-93.3)
  N2-3 51 (25.8-76.8) 69 (56.3-81.7)
PS (ECOG)   0.004   0.003
  0 62 (44.3-80.0)   85 (73.3-96.1)  
  1 26 (5.5-47.5) 52 (34.4-69.6)
Induction response   0.549   0.002
  CR 53 (29.2-75.8) 94 (91.8-105.8)
  Non-CR 54 (39.2-69.0) 61 (47.2-74.2)
RT dose (cGy)   0.233   0.006
  ≥6,500 57 (41.6-73.0) 80 (67.5-92.5)
  <6,500 46 (24.7-67.1) 56 (38.4-73.6)
RT type   0.132   0.198
  3D-RT 59 (42.5-67.8) 74 (62.0-86.4)
  IMRT 73 (50.5-92.5) 88.1 (78.1-98.1)
Treatment duration   0.702   0.258
  <4 months 59 (36.3-81.0) 75 (58.4-91.0)
  ≥4 months 53 (36.6-68.8) 67 (53.3-81.5)
HPV   0.078   0.136
  Positive 71 (52.0-90.8) 81 (64.1-98.0)
  Negative 45 (29.0-60.4) 66 (52.5-79.1)
p16   0.076   0.014
  Positive 61 (43.4-78.6) 83 (70.4-95.4)
  Negative 46 (28.2-63.4) 59 (42.6-75.2)
p53   0.655   0.002
  Low 43 (25.5-71.7) 81 (69.8-92.2)
  High 49 (28.0-58.2) 50 (30.1-70.5)
ERCC1   0.491   0.355
  Low 53 (31.2-74.4) 64 (48.3-78.9)
  High 54 (26.8-82.0) 70 (41.3-99.3)
Class III beta tubulin   0.098   0.012
  Low 58 (43.1-72.5) 77 (65.4-89.4)
  High 42 (18.4-66.2) 54 (32.5-74.9)
Bcl-2   0.678   0.217
  Low 57 (40.6-72.8) 64 (48.3-78.9)
  High 54 (26.8-82.0) 70 (41.2-99.3)
  1. Abbreviation: CR complete response.